JP Morgan Chase
RLAY icon

JP Morgan Chase’s Relay Therapeutics RLAY Stock Holding History

JP Morgan Chase’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16M Buy
801,657
+154,139
+24% +$2.24M ﹤0.01% 2403
2026
Q1 		$6.05M Buy
647,518
+221,560
+52% +$1.98M ﹤0.01% 3140
2025
Q4 		$3.6M Sell
425,958
-36,421
-8% -$260K ﹤0.01% 3609
2025
Q3 		$2.41M Sell
462,379
-3,876,024
-89% -$14.8M ﹤0.01% 3940
2025
Q2 		$15M Sell
4,338,403
-571,368
-12% -$1.7M ﹤0.01% 2179
2025
Q1 		$12.9M Sell
4,909,771
-68,672
-1% -$269K ﹤0.01% 2323
2024
Q4 		$20.5M Sell
4,978,443
-539,073
-10% -$2.93M ﹤0.01% 2026
2024
Q3 		$39.1M Buy
5,517,516
+1,554,115
+39% +$11.6M ﹤0.01% 1489
2024
Q2 		$25.8M Buy
3,963,401
+246,133
+7% +$1.68M ﹤0.01% 1670
2024
Q1 		$30.9M Sell
3,717,268
-2,348,327
-39% -$22.9M ﹤0.01% 1588
2023
Q4 		$66.8M Buy
6,065,595
+929,111
+18% +$7.84M 0.01% 1077
2023
Q3 		$43.2M Buy
5,136,484
+141,579
+3% +$1.52M ﹤0.01% 1183
2023
Q2 		$62.7M Buy
4,994,905
+694,079
+16% +$8.63M 0.01% 1018
2023
Q1 		$70.8M Sell
4,300,826
-169,072
-4% -$3.03M 0.01% 941
2022
Q4 		$66.8M Sell
4,469,898
-548,589
-11% -$10.5M 0.01% 958
2022
Q3 		$112M Buy
5,018,487
+76,225
+2% +$1.67M 0.02% 678
2022
Q2 		$82.8M Buy
4,942,262
+1,667,873
+51% +$35.7M 0.01% 819
2022
Q1 		$98M Sell
3,274,389
-92,923
-3% -$2.25M 0.01% 849
2021
Q4 		$103M Buy
3,367,312
+1,940,330
+136% +$61.3M 0.01% 869
2021
Q3 		$45M Buy
1,426,982
+3,655
+0.3% +$123K 0.01% 1233
2021
Q2 		$52.1M Buy
1,423,327
+43,821
+3% +$1.44M 0.01% 1205
2021
Q1 		$47.7M Buy
1,379,506
+88,977
+7% +$3.86M 0.01% 1182
2020
Q4 		$53.6M Buy
1,290,529
+76,091
+6% +$3.44M 0.01% 1034
2020
Q3 		$48.6M Buy
+1,214,438
New +$46.3M 0.01% 988

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

JP Morgan Chase's RLAY Position: Q2 2026 in Review

JP Morgan Chase increased its Relay Therapeutics (RLAY) stake by 24% in Q2 2026, buying an estimated $2.24M and bringing the position to 801,657 shares worth $16M. The position accounts for ﹤0.01% of the portfolio, ranked #2403.

JP Morgan Chase first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. The position peaked at $112M in Q3 2022. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • JP Morgan Chase held 801,657 shares of Relay Therapeutics worth $16M as of Q2 2026.
  • JP Morgan Chase bought 154,139 Relay Therapeutics shares in Q2 2026, an estimated $2.24M.
  • Relay Therapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2403 holding.
  • JP Morgan Chase first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • JP Morgan Chase's Relay Therapeutics position peaked at $112M in Q3 2022.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.